H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Veru Inc (NASDAQ: VERU) yesterday and set a price target of $5. The company’s shares closed yesterday at $2.25.
Selvaraju wrote:
“We note that VERU-944 is a 505(b) (2) candidate due to the existing preclinical and clinical information on clomiphene citrate, which is indicated to treat infertility in women. Veru plans to advance the candidate into a double-blind, placebo- controlled dose-finding Phase 2 study that could enroll approximately 120 patients. The primary endpoint is the change in frequency of ADT- induced moderate and severe hot flashes over a 12-week period. We believe this trial could dose the first patient in summer 2018 and report top-line results in 1H 2019. In the wake of this update, we reiterate our Buy rating and $5 price target.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.8% and a 40.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Veru Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3 and a one-year low of $0.90. Currently, Veru Inc has an average volume of 145.7K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERU in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veru, Inc. is a urology and oncology biopharmaceutical company, which engages in the development, manufacture, and marketing of consumer health care products. It operates through the Commercial; and Research and Development segments.
